Neurology
Found 7 results
Filters: Keyword is Disease Progression and Author is Gauthier, Susan A  [Clear All Filters]
2022
Longbrake EE, Hua LH, Mowry EM, Gauthier SA, Alvarez E, Cross AH, Pei J, Priest J, Raposo C, Hafler DA et al..  2022.  The CELLO trial: Protocol of a planned phase 4 study to assess the efficacy of Ocrelizumab in patients with radiologically isolated syndrome.. Mult Scler Relat Disord. 68:104143.
Marcille M, Rúa SHurtado, Tyshkov C, Jaywant A, Comunale J, Kaunzner UW, Nealon N, Perumal JS, Zexter L, Zinger N et al..  2022.  Disease correlates of rim lesions on quantitative susceptibility mapping in multiple sclerosis.. Sci Rep. 12(1):4411.
Pitt D, Lo CHung, Gauthier SA, Hickman RA, Longbrake E, Airas LM, Mao-Draayer Y, Riley C, De Jager PLawrence, Wesley S et al..  2022.  Toward Precision Phenotyping of Multiple Sclerosis.. Neurol Neuroimmunol Neuroinflamm. 9(6)
2020
Bagnato F, Gauthier SA, Laule C, Moore GRWayne, Bove R, Cai Z, Cohen-Adad J, Harrison DM, Klawiter EC, Morrow SA et al..  2020.  Imaging Mechanisms of Disease Progression in Multiple Sclerosis: Beyond Brain Atrophy.. J Neuroimaging. 30(3):251-266.
2018
Kocsik AS, Klein DE, Liedke M, Kaunzner UW, Nealon NM, Gauthier SA, Vartanian T, Perumal JS.  2018.  Induction of disease remission with one cycle of alemtuzumab in relapsing-remitting MS.. J Neurol. 265(5):1226-1229.
2016
Chiang GC, Pinto S, Comunale JP, Gauthier SA.  2016.  Gadolinium-Enhancing Lesions Lead to Decreases in White Matter Tract Fractional Anisotropy in Multiple Sclerosis.. J Neuroimaging. 26(3):289-95.
Zhang Y, Gauthier SA, Gupta A, Comunale J, Chiang GChia-Yi, Zhou D, Chen W, Giambrone AE, Zhu W, Wang Y.  2016.  Longitudinal change in magnetic susceptibility of new enhanced multiple sclerosis (MS) lesions measured on serial quantitative susceptibility mapping (QSM).. J Magn Reson Imaging. 44(2):426-32.